PharmGKB VIP Summary for CYP4F2 published in Pharmacogenetics and Genomics

The PharmGKB Very Important Pharmacogene (VIP) summary describing important pharmacogenetic variants in CYP4F2 was recently published by Pharmacogenetics & Genomics. Cytochrome p450, family 2, subfamily F, polypeptide 2 (CYP4F2) catalyzes the oxidation of the terminal carbon of the side chains of vitamin K, vitamin E, arachidonic acid (AA), and leukotriene B4 (LTB 4). Thus, CYP4F2 plays a role in the regulation of the inflammation response, blood pressure as well as vitamin K and vitamin E bioavailability. A single genetic variant (rs2108622 C>T also known as CYP4F2 *3) has consistently demonstrated a small but significant effect on warfarin and acenocoumarol dosage and safety, particularly in Caucasian and Asian populations.

View an interactive version:

CYP4F2 VIP Summary on PharmGKB

Read the publication:

PharmGKB summary: very important pharmacogene information for CYP4F2
Pharmacogenetics & Genomics. 2014 Nov 3. (Epub ahead of print)Alvarellos ML, Sangkuhl K, Daneshjou R, Whirl-Carrillo M, Altman RB, Klein TE.

Subscribe to ClinPGx Blog

Don’t miss out on the latest issues. Sign up now to get access to the library of members-only issues.